CD274 and ovarian carcinoma: Beyond these approved sequential anti-PD-1-after-antiangiogenic combinations, there are at least five ongoing randomised phase 3 trials evaluating concurrent anti-PD-L1-plus-antiangiogenic combinations in late-stage (inoperable) RCC, non-small-cell lung cancer, and ovarian cancer (Suppl.